Neuropeptide Y Is Produced by Adipose Tissue Macrophages and Regulates Obesity-Induced Inflammation

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Singer, Kanakadurga ^a   Morris, David L ^a   Oatmen, Kelsie E ^a   Wang, Tianyi ^a   DelProposto, Jennifer ^a   Mergian, Taleen ^a   Cho, Kae Won ^a   Lumeng, Carey N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUROPEPTIDE Y; TUMOR NECROSIS FACTOR ALPHA; NEUROPEPTIDE Y RECEPTOR; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; HEMATOPOIETIC CELL; IN VITRO STUDY; INFLAMMATION; INTRAABDOMINAL FAT; LIPID DIET; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; OBESITY; PARACRINE SIGNALING; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CYTOLOGY; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; INSULIN RESISTANCE; METABOLISM; MOUSE MUTANT;

ADIPOSE TISSUE; ANIMALS; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MONOCYTES; NEUROPEPTIDE Y; OBESITY; RECEPTORS, NEUROPEPTIDE Y; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874641220     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057929     Document Type: Article

References (52)

1. Berg AH, Scherer PE, (2005) Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949.
2. Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, et al. (2010) Expression of inflammatory molecules and associations with BMI in children. Eur J Clin Invest 40: 388-392.
3. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM, (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415.
4. Lumeng CN, Bodzin JL, Saltiel AR, (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175-184.
5. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, et al. (2009) Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 94: 4619-4623.
6. Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, et al. (2009) MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 206: 3143-3156.
7. Robbins CS, Chudnovskiy A, Rauch PJ, Figueiredo JL, Iwamoto Y, et al. (2011) Extramedullary Hematopoiesis Generates Ly-6Chigh Monocytes that Infiltrate Atherosclerotic Lesions. Circulation.
8. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, et al. (2010) Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 120: 3466-3479.
9. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
10. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, et al. (2008) Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 1: 36-43.
11. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, et al. (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8: 301-309.
12. Kyrou I, Chrousos GP, Tsigos C, (2006) Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci 1083: 77-110.
13. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP, (2010) Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther 126: 159-172.
14. Heilig M, (2004) The NPY system in stress, anxiety and depression. Neuropeptides 38: 213-224.
15. Dimitrijevic M, Stanojevic S, Vujic V, Beck-Sickinger A, von Horsten S, (2005) Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors. Regul Pept 124: 163-172.
16. Ruohonen ST, Pesonen U, Moritz N, Kaipio K, Roytta M, et al. (2008) Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. Diabetes 57: 1517-1525.
17. Kos K, Baker AR, Jernas M, Harte AL, Clapham JC, et al. (2009) DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 11: 285-292.
18. Yang K, Guan H, Arany E, Hill DJ, Cao X, (2008) Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J 22: 2452-2464.
19. Segal-Lieberman G, Trombly DJ, Juthani V, Wang X, Maratos-Flier E, (2003) NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. Am J Physiol Endocrinol Metab 284: E1131-1139.
20. Kuo LE, Czarnecka M, Kitlinska JB, Tilan JU, Kvetnansky R, et al. (2008) Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. Ann N Y Acad Sci 1148: 232-237.
21. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, et al. (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13: 803-811.
22. Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, et al. (2003) Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 171: 3451-3458.
23. Stadler J, Le TP, Haas P, Nave H, (2011) Distinct effects of NPY13-36, a specific NPY Y2 agonist, in a model of rodent endotoxemia on leukocyte subsets and cytokine levels. Annals of anatomy = Anatomischer Anzeiger: official organ of the Anatomische Gesellschaft 193: 486-493.
24. Bedoui S, Kuhlmann S, Nave H, Drube J, Pabst R, et al. (2001) Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J Neuroimmunol 117: 125-132.
25. Nave H, Bedoui S, Moenter F, Steffens J, Felies M, et al. (2004) Reduced tissue immigration of monocytes by neuropeptide Y during endotoxemia is associated with Y2 receptor activation. J Neuroimmunol 155: 1-12.
26. Wheway J, Herzog H, Mackay F, (2007) The Y1 receptor for NPY: a key modulator of the adaptive immune system. Peptides 28: 453-458.
27. Gelfo F, De Bartolo P, Tirassa P, Croce N, Caltagirone C, et al. (2011) Intraperitoneal injection of neuropeptide Y (NPY) alters neurotrophin rat hypothalamic levels: Implications for NPY potential role in stress-related disorders. Peptides 32: 1320-1323.
28. Morris DL, Oatmen KE, Wang T, DelProposto JL, Lumeng CN, (2012) CX3CR1 deficiency does not influence trafficking of adipose tissue macrophages in mice with diet-induced obesity. Obesity (Silver Spring) 20: 1189-1199.
29. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR, (2008) Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 57: 3239-3246.
30. Erickson JC, Clegg KE, Palmiter RD, (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 381: 415-421.
31. Kakko T, Jaakkola U, Raitakari OT, Kallio J, (2011) Inflammatory effects of blood leukocytes: association with vascular function in neuropeptide Y proline 7-genotyped type 2 diabetes patients. Diab Vasc Dis Res 8: 221-228.
32. Abid K, Rochat B, Lassahn PG, Stocklin R, Michalet S, et al. (2009) Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein. J Biol Chem 284: 24715-24724.
33. Schwarz H, Villiger PM, von Kempis J, Lotz M, (1994) Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 51: 53-61.
34. El Kasmi KC, Smith AM, Williams L, Neale G, Panopoulos AD, et al. (2007) Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol 179: 7215-7219.
35. Chen SH, Han QD, (1995) Increase of release of neuropeptide Y in vitro from platelets of spontaneously hypertensive rats. Zhongguo yao li xue bao = Acta pharmacologica Sinica 16: 149-152.
36. Myers AK, Farhat MY, Vaz CA, Keiser HR, Zukowska-Grojec Z, (1988) Release of immunoreactive-neuropeptide by rat platelets. Biochemical and biophysical research communications 155: 118-122.
37. Silva AP, Cavadas C, Baisse-Agushi B, Spertini O, Brunner HR, et al. (2003) NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. Regulatory peptides 116: 71-79.
38. Makinde TO, Steininger R, Agrawal DK (2012) NPY and NPY receptors in airway structural and inflammatory cells in allergic asthma. Exp Mol Pathol.
39. Barnea A, Roberts J, Keller P, Word RA, (2001) Interleukin-1beta induces expression of neuropeptide Y in primary astrocyte cultures in a cytokine-specific manner: induction in human but not rat astrocytes. Brain research 896: 137-145.
40. Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, et al. (2003) Chronic stress and obesity: a new view of "comfort food". Proc Natl Acad Sci U S A 100: 11696-11701.
41. Rasmusson AM, Schnurr PP, Zukowska Z, Scioli E, Forman DE, (2010) Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome. Exp Biol Med (Maywood) 235: 1150-1162.
42. Hauser GJ, Dayao EK, Zukowska-Grojec Z, (1995) Effect of neuropeptide Y on endotoxin-induced suppression of the response to various agonists in conscious rats. Life Sci 57: 235-244.
43. Qureshi NU, Dayao EK, Shirali S, Zukowska-Grojec Z, Hauser GJ, (1998) Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock. Regul Pept 75-76: 215-220.
44. Gundersen C, Mahatmya D, Garasky S, Lohman B (2010) Linking psychosocial stressors and childhood obesity. Obes Rev.
45. Kivimaki M, Head J, Ferrie JE, Shipley MJ, Brunner E, et al. (2006) Work stress, weight gain and weight loss: evidence for bidirectional effects of job strain on body mass index in the Whitehall II study. Int J Obes (Lond) 30: 982-987.
46. Mitic K, Stanojevic S, Kustrimovic N, Vujic V, Dimitrijevic M, (2011) Neuropeptide Y modulates functions of inflammatory cells in the rat: distinct role for Y1, Y2 and Y5 receptors. Peptides 32: 1626-1633.
47. Lee YS, Li P, Huh JY, Hwang IJ, Lu M, et al. (2011) Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes 60: 2474-2483.
48. Patel HR, Qi Y, Hawkins EJ, Hileman SM, Elmquist JK, et al. (2006) Neuropeptide Y deficiency attenuates responses to fasting and high-fat diet in obesity-prone mice. Diabetes 55: 3091-3098.
49. Mori MA, Liu M, Bezy O, Almind K, Shapiro H, et al. (2010) A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease. Diabetes 59: 2960-2971.
50. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, et al. (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124: 2338-2349.
51. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, et al. (2010) Dipeptidyl peptidase-4 inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab.
52. Kim SJ, Nian C, McIntosh CH, (2010) Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and-independent pathways. Diabetes 59: 1739-1750.